Abstract:Domain-aware artificial intelligence has been increasingly adopted in recent years to expedite molecular design in various applications, including drug design and discovery. Recent advances in areas such as physics-informed machine learning and reasoning, software engineering, high-end hardware development, and computing infrastructures are providing opportunities to build scalable and explainable AI molecular discovery systems. This could improve a design hypothesis through feedback analysis, data integration that can provide a basis for the introduction of end-to-end automation for compound discovery and optimization, and enable more intelligent searches of chemical space. Several state-of-the-art ML architectures are predominantly and independently used for predicting the properties of small molecules, their high throughput synthesis, and screening, iteratively identifying and optimizing lead therapeutic candidates. However, such deep learning and ML approaches also raise considerable conceptual, technical, scalability, and end-to-end error quantification challenges, as well as skepticism about the current AI hype to build automated tools. To this end, synergistically and intelligently using these individual components along with robust quantum physics-based molecular representation and data generation tools in a closed-loop holds enormous promise for accelerated therapeutic design to critically analyze the opportunities and challenges for their more widespread application. This article aims to identify the most recent technology and breakthrough achieved by each of the components and discusses how such autonomous AI and ML workflows can be integrated to radically accelerate the protein target or disease model-based probe design that can be iteratively validated experimentally. Taken together, this could significantly reduce the timeline for end-to-end therapeutic discovery and optimization upon the arrival of any novel zoonotic transmission event. Our article serves as a guide for medicinal, computational chemistry and biology, analytical chemistry, and the ML community to practice autonomous molecular design in precision medicine and drug discovery.

The promise and pitfalls of AI for molecular and materials synthesis

AI in Chemical Engineering: A New Chapter of Innovation

AI for organic and polymer synthesis

Current and Future Roles of Artificial Intelligence in Medicinal Chemistry Synthesis

Automation, analytics and artificial intelligence for chemical synthesis

Artificial-Intelligence-Driven Organic Synthesis-En Route towards Autonomous Synthesis?

Challenges and opportunities for AI in synthetic solid-state inorganic chemistry

Impact of Artificial Intelligence on Compound Discovery, Design, and Synthesis

Combinatorial synthesis for AI-driven materials discovery

Artificial Intelligence for Retrosynthetic Planning Needs Both Data and Expert Knowledge

The Process of AI-Aided Drug Design

Molecule Maker Lab Institute: Accelerating, advancing, and democratizing molecular innovation

Scientific AI in materials science: a path to a sustainable and scalable paradigm

Role of AI in experimental materials science

Preface: Paving the Road for AI in Molecular Sciences

In Silico Chemical Experiments in the Age of AI: From Quantum Chemistry to Machine Learning and Back

Toward autonomous design and synthesis of novel inorganic materials.

The Future of Material Scientists in an Age of Artificial Intelligence

Self-Driving Laboratories for Development of New Functional Materials and Optimizing Known Reactions

An autonomous laboratory for the accelerated synthesis of novel materials

Artificial Intelligence for Autonomous Molecular Design: A Perspective